Evidence map›Paper›PMID 39843857›Full record

ArticleHypertension research : official journal of the Japanese Society of Hypertension2025

Blood pressure variability as predictor of cancer therapy-related cardiovascular toxicity in patients with Multiple Myeloma.

Elvira Fanelli, Giulia Picca, Lorenzo Airale, Anna Astarita, Giulia Mingrone, Cinzia Catarinella, Simona Votta, Anna Colomba, Marco Cesareo, Dario Leone and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Recent updates and perspectives in "Onco-hypertension".Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Elvira FanelliDivision of Internal Medicine, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy. elvirafanelli@hotmail.it.
Giulia PiccaDivision of Internal Medicine, Hypertension Unit, A.O.U. Città della Salute e della Scienza di Torino, Department of Medical Sciences, University of Turin, Turin, Italy.
Lorenzo AiraleDivision of Internal Medicine, Hypertension Unit, A.O.U. Città della Salute e della Scienza di Torino, Department of Medical Sciences, University of Turin, Turin, Italy.
Anna AstaritaDepartment of Medical Sciences, University of Turin, Turin, Italy.
Giulia MingroneDivision of Internal Medicine, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.
Cinzia CatarinellaDivision of Internal Medicine, Hypertension Unit, A.O.U. Città della Salute e della Scienza di Torino, Department of Medical Sciences, University of Turin, Turin, Italy.
Simona VottaDivision of Internal Medicine, Hypertension Unit, A.O.U. Città della Salute e della Scienza di Torino, Department of Medical Sciences, University of Turin, Turin, Italy.
Anna ColombaDivision of Internal Medicine, Hypertension Unit, A.O.U. Città della Salute e della Scienza di Torino, Department of Medical Sciences, University of Turin, Turin, Italy.
Marco CesareoDivision of Internal Medicine, Hypertension Unit, A.O.U. Città della Salute e della Scienza di Torino, Department of Medical Sciences, University of Turin, Turin, Italy.
Dario LeoneDivision of Internal Medicine, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.
Arianna PaladinoDivision of Internal Medicine, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.
Franco RabbiaDivision of Internal Medicine, Hypertension Unit, A.O.U. Città della Salute e della Scienza di Torino, Department of Medical Sciences, University of Turin, Turin, Italy.
Sara BringhenSSD Clinical Trial in Oncoematologia e Mieloma Multiplo, Division of Hematology, AOU Città della Salute e della Scienza di Torino, Turin, Italy.
Francesca GaySSD Clinical Trial in Oncoematologia e Mieloma Multiplo, Division of Hematology, AOU Città della Salute e della Scienza di Torino, Turin, Italy.
Franco VeglioDivision of Internal Medicine, Hypertension Unit, A.O.U. Città della Salute e della Scienza di Torino, Department of Medical Sciences, University of Turin, Turin, Italy.
Alberto MilanDivision of Internal Medicine, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.
Fabrizio VallelongaDivision of Internal Medicine, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Blood pressure (BP) variability (BPV) is an independent predictor of cardiovascular (CV) events. The role of BPV in defining risk of cancer therapy-related cardiovascular toxicity (CTR-CVT) is currently unknown. The aims of this study were: (i) to evaluate BPV in a population of patients with Multiple Myeloma, undergoing proteasome inhibitors therapy; (ii) to assess the predictive value of BPV for CTR-CVT; (iii) to analyze clusters of subjects based on BPV. One hundred twenty-four patients underwent a baseline evaluation, including Ambulatory Blood Pressure Monitoring (ABPM), PWV, and Echocardiography. BPV was assessed through ABPM-based standard deviation (SD), weighted standard deviation (wSD), coefficient of variation (CoV), average real variability (ARV), and variability independent of the mean (VIM). Individuals who developed CTR-CVT had a higher baseline BPV. Furthermore, night-time BPV was associated with CTR-CVT, independently of age, smoking, BP, diabetes, dyslipidemia, and kidney function (night-time systolic CoV: adjusted OR 1.09 [1.01-1.21]; night-time systolic VIM: adjusted OR 1.18 [1.01-1.39]). Cut-offs for these BPV parameters were identified as predictors of CTR-CVT occurrence: 10.5 for night-time systolic CoV; 7.8 and 6.4 for systolic and diastolic night-time VIM. Clustering analysis identified subgroups of subjects characterized by the highest BPV, who had a greater prevalence of events, but no differences in other CV risk determinants. Short-term BPV is an independent predictor of CTR-CVT. BPV may enhance the precision of risk stratification in cancer patients, enabling identification of individuals at higher risk who would not be recognized, if traditional prognostic indicators were the sole applied criteria. On the left panel in the figure, the distribution of blood pressure variability (BPV) in the population according to cancer therapy-related cardiovascular toxicity occurrence; in the central panel, association of blood pressure variability with events and cutoffs values; in the right panel, clustering analysis results based on BPV levels. Histogram and radar plot represent events and BPV indexes distribution in the three clusters, respectively. ARV, average real variability; BPV, Blood Pressure Variability; CTR-CVT, cancer therapy-related cardiovascular toxicity; CoV, coefficient of variation; DBP, Diastolic blood pressure; SBP, Systolic blood pressure; SD, standard deviation; VIM, variability independent of the mean; wSD, weighted standard deviation.

Indexed as

Blood PressureCardiovascular DiseasesMultiple MyelomaProteasome InhibitorsAgedBlood Pressure Monitoring, AmbulatoryCardiotoxicityFemaleHumansMaleMiddle AgedProteasome InhibitorsBPVCadioOncologyCardiovascular toxicityRisk prediction

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.